Cure8

Why This Matters

This project investigates how estrogen receptor signaling in intestinal epithelial cells drives sex-specific responses to injury and inflammation that may influence ulcerative colitis risk and progression.

Who Should Pay Attention

Researchers (sex differences, epithelial biology, IBD), clinicians caring for IBD patients, and patients curious about hormonal influences on gut inflammation

Study Snapshot

Story typeClinical Reference
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record

What To Know

The project will use mouse models (including ER knockouts), organoid assays, and molecular profiling to define how ERα and ERβ expression and signaling change after intestinal injury (DSS colitis) and how estrogen and inflammatory pathways converge in male versus female intestinal epithelial cells.

The investigators aim to produce a model explaining how altered estrogen signaling contributes to epithelial dysfunction and sex-specific colonic inflammation. The work is a basic/translational research project (funded) focused on mechanisms, not a clinical trial of a treatment.

Outcomes are intended to inform future personalized-medicine approaches by clarifying hormonal influences on intestinal inflammation.

Keep In Mind

Project-record describing funded basic and translational lab and mouse studies; not a clinical trial and not a report of patient outcomes. Translation to humans will require further study.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Funded research project Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsWendy Ann Goodman
InstitutionCASE WESTERN RESERVE UNIVERSITY
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 10, 2026, 12:00 AM
Content availableResearch project record

Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R56DK145554 - $300,000

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →